Target intelligence / Profile preview

Cerebral vascular smooth muscle cell (VSMC)

Target
VSMC
Molecular classification
Other (contractile cell)
01

Overview

Cerebral vascular smooth muscle cells (VSMCs) are specialized contractile cells that envelope cerebral arteries and arterioles, regulating blood vessel diameter and thus cerebral blood flow. They respond to chemical mediators (e.g., neurotransmitters, hormones), mechanical stimuli, and changes in local metabolic demand by contracting or relaxing, playing a central role in the maintenance of adequate brain perfusion and blood-brain barrier integrity. VSMCs express a variety of receptors (including adrenergic, angiotensin, and endothelin receptors), ion channels, and adhesion molecules, making them responsive to diverse regulatory pathways. Dysfunction or maladaptive phenotypic switching of VSMCs is implicated in multiple cerebrovascular and neurodegenerative diseases.

Other names
Vascular smooth muscle cell (of cerebral blood vessels)Cerebral VSMCSmooth muscle cell (brain vasculature)
02

Mechanism of action

Inhibition of calcium influx (vasodilation via L-type calcium channel blockade). Adrenergic receptor antagonism or agonism (modulating contraction/relaxation). Modulation of RAS (reducing vasoconstriction by angiotensin II). NO pathway activation (vasodilation via increased NO).

03

Biological functions

Regulation of cerebral blood flowMaintenance of cerebrovascular toneVasoconstriction and vasodilationResponse to chemical and mechanical signals (including mechanotransduction)Blood-brain barrier regulation (indirectly via vessel tone and integrity)
04

Disease associations

Cerebrovascular disease (e.g., small vessel disease, stroke)Cardiovascular diseaseNeurodegenerative disease (e.g., vascular contributions to Alzheimer's disease, CAA)Atherosclerosis and restenosis after vascular injury
05

Safety considerations

Excessive vasoconstriction or vasodilation affecting cerebral perfusionOff-target systemic hypotensionVascular remodeling contributing to chronic pathology (e.g., atherosclerosis, restenosis after intervention)
06

Interacting drugs

Calcium channel blockers (e.g., nimodipine)

3 more in the full profile.

07

Biomarkers

VSMC dysfunction as a biomarker for vascular disease and progression (e.g., changes in expression of smooth muscle actin, myosin heavy/light chain isoforms)

Beyond the preview

Go deeper on Cerebral vascular smooth muscle cell (VSMC).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cerebral vascular smooth muscle cell (VSMC).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call